CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
This is a prospective, single-center, non-randomized, non-controlled observational study.
Almost 55-62% of patients with triple-negative or human epidermal growth factor receptor 2
 (HER2) positive, node-positive breast cancer achieve an axillary pathologic complete
 remission (pCR) after neoadjuvant chemotherapy (NAC). To avoid surgery post-NAC, it is
 paramount to accurately identify patients who achieve pCR in axillary lymph node (ALN). We
 found that patients with normal-appearing lymph nodes on computed tomography (CT) based
 radiomics of the axilla after chemotherapy had a lower risk of developing residual nodal
 disease. However, the features of CT-based radiomics for pCR ALN following NAC has not been
 established yet. This study aimed to assess the performance of CT-based radiomics in
 evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast
 cancer patients.
Inclusion Criteria:

 -  Triple-negative or HER2-positve invasive breast cancer with axillary lymph node
 metastasis by confirmed by fine needle aspiration or core needle biopsy.

 -  Underwent computed tomography for assessment of axillary lymph node status before and
 after neoadjuvant chemotherapy.

 -  Attend the study voluntarily, sign the informed consent.

 Exclusion Criteria:

 -  Contradiction for adjuvant chemotherapy.

 -  Contradiction for proceeding surgery.